Consensus on the treatment of asthma in pediatrics;Consenso sobre tratamiento del asma en pediatría

Anales de Pediatria

Volumn 64, Issue 4, 2006, Pages 365-378

  Busquets Monge, R M ^a   Escribano Montaner, A ^a   Fernandez Benitez M ^b   Garcia Marcos L ^a,b,c   Garde Garde, J ^b   Ibero Iborra, M ^b   Pardos Rocamora, L ^a   Sanchez Jimenez J ^a   Sanchez Sanchez E ^a   Sanz Ortega, J ^b   Villa Asensi, J R ^a  

^a Sociedad Española de Neumología Pediátrica SENP   (Spain)

^b Sociedad Española de Inmunología y Alergia Pediátrica SEICAP   (Spain)

^c Sociedad Espanola de Neumologia Pediatrica   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; GLUCOCORTICOID; IPRATROPIUM BROMIDE;

ALLERGY; ASTHMA; CHILD HEALTH CARE; DISEASE CLASSIFICATION; DISEASE SEVERITY; DYSPNEA; FORCED EXPIRATORY VOLUME; HUMAN; NEBULIZATION; PHENOTYPE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SPAIN; SYMPTOMATOLOGY;

EID: 33646847850     PISSN: 16954033     EISSN: None     Source Type: Journal    
DOI: 10.1157/13086527     Document Type: Article

References (120)

1. García-Marcos L, Quirós AB, Hernández GG, Guillén-Grima F, Díaz CG, Urena IC, et al. Stabilization of asthma prevalence among adolescents and increase among schoolchildren (ISAAC phases I and III) in Spain. Allergy. 2004;59:1301-7.
2. Aguinaga OI, Arnedo PA, Bellido J, Guillén GF, Suárez Varela MM. The prevalence of asthma-related symptoms in 13-14-year-old children from 9 Spanish populations. The Spanish Group of the ISAAC Study (International Study of Asthma and Allergies in Childhood). Med Clin (Barc). 1999;112:171-5.
3. Carvajal-Uruena I, García-Marcos L, Busquets-Monge R, Morales Suárez-Varela M, García DA, Batlles-Garrido J, et al. Variaciones geográficas en la prevalencia de síntomas de asma en los ninos y adolescentes espanoles. International Study of Asthma and Allergies in Childhood (ISAAC) fase III Espana. Arch Bronconeumol. 2005;41:659-66.
4. Davies DP. Asthma: a follow up statement from an international paediatric asthma consensus group. Arch Dis Child. 1992;67:240-8.
5. Warner JO, Naspitz CK. Third International Pediatric Consensus statement on the management of childhood asthma. International Pediatric Asthma Consensus Group. Pediatr Pulmonol. 1998;25:1-17.
6. Global Strategy for Asthma Management and Prevention. National Institutes of Health National Heart, Lung, and Blood Institute 2002. Maryland: Bethesda; 2002.
7. A sixth-part asthma management program. En: Global Strategy for Asthma Management and Prevention. Maryland: Bethesda; 2002. p. 102.
8. Plaza Moral V, Álvarez Gutiérrez FJ, Casán Clará P, Cobos Barroso N, López Viña A, Llauger Roselló MA, et al. Guía española para el manejo del asma (GEMA). Arch Bronconeumol. 2003;39 Supl 15:1-42.
9. Halonen M, Stern DA, Lohman C, Wright AL, Brown MA, Martinez FD. Two subphenotypes of childhood asthma that differ in maternal and paternal influences on asthma risk. Am J Respir Crit Care Med. 1999;160:564-70.
10. Kozyrskyj AL, Mustard CA, Becker AB. Childhood wheezing syndromes and healthcare data. Pediatr Pulmonol. 2003;36:131-6.
11. Kurukulaaratchy RJ, Fenn MH, Waterhouse LM, Matthews SM, Holgate ST, Arshad SH. Characterization of wheezing phenotypes in the first 10 years of life. Clin Exp Allergy. 2003;33:573-8.
12. London SJ, James GW, Avol E, Rappaport EB, Peters JM. Family history and the risk of early-onset persistent, early-onset transient, and late-onset asthma. Epidemiology. 2001;12:577-83.
13. Martínez FD, Wright AL, Taussig LM, Holberg CJ, Halonen M, Morgan WJ. Asthma and wheezing in the first six years of life. The Group Health Medical Associates. N Engl J Med. 1995;332:133-8.
14. Martínez FD. What have we learned from the Tucson Children's Respiratory Study? Paediatr Respir Rev. 2002;3:193-7.
15. Najafi N, Demanet C, Dab I, De Waele M, Malfroot A. Differential cytology of bronchoalveolar lavage fluid in asthmatic children. Pediatr Pulmonol. 2003;35:302-8.
16. Stein RT, Holberg CJ, Morgan WJ, Wright AL, Lombardi E, Taussig L, et al. Peak flow variability, methacholine responsiveness and atopy as markers for detecting different wheezing phenotypes in childhood. Thorax. 1997;52:946-52.
17. Stein RT, Sherrill D, Morgan WJ, Holberg CJ, Halonen M, Taussig LM, et al. Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years. Lancet. 1999;354:541-5.
18. Stevenson EC, Turner G, Heaney LG, Schock BC, Taylor R, Gallagher T, et al. Bronchoalveolar lavage findings suggest two different forms of childhood asthma. Clin Exp Allergy. 1997;27:1027-35.
19. Taussig LM, Wright AL, Holberg CJ, Halonen M, Morgan WJ, Martínez FD. Tucson Children's Respiratory Study: 1980 to present. J Allergy Clin Immunol. 2003;111:661-75.
20. Castro-Rodríguez JA, Holberg CJ, Wright AL, Martínez FD. A clinical index to define risk of asthma in young children with recurrent wheezing. Am J Respir Crit Care Med. 2000; 162:1403-6.
21. Kulig M, Bergmann R, Klettke U, Wahn V, Tacke U, Wahn U. Natural course of sensitization to food and inhalant allergens during the first 6 years of life. J Allergy Clin Immunol. 1999; 103:1173-9.
22. Sasai K, Furukawa S, Muto T, Baba M, Yabuta K, Fukuwatari Y. Early detection of specific IgE antibody against house dust mite in children at risk of allergic disease. J Pediatr. 1996;128:834-40.
23. Tariq SM, Matthews SM, Hakim EA, Arshad SH. Egg allergy in infancy predicts respiratory allergic disease by 4 years of age. Pediatr Allergy Immunol. 2000;11:162-7.
24. Bentur L, Canny GJ, Shields MD, Kerem E, Schuh S, Reisman JJ, et al. Controlled trial of nebulized albuterol in children younger than 2 years of age with acute asthma. Pediatrics. 1992;89:133-7.
25. Kraemer R, Graf BU, Casaulta AC, Weder M, Birrer P. Clinical and physiological improvement after inhalation of low-dose beclomethasone dipropionate and salbutamol in wheezy infants. Respiration. 1997;64:342-9.
26. Fox GF, Marsh MJ, Milner AD. Treatment of recurrent acute wheezing episodes in infancy with oral salbutamol and prednisolone. Eur J Pediatr. 1996;155:512-6.
27. Prendiville A, Green S, Silverman M. Bronchial responsiveness to histamine in wheezy infants. Thorax. 1987;42:92-9.
28. Prendiville A, Green S, Silverman M. Paradoxical response to nebulised salbutamol in wheezy infants, assessed by partial expiratory flow-volume curves. Thorax. 1987;42:86-91.
29. Prendiville A, Green S, Silverman M. Airway responsiveness in wheezy infants: Evidence for functional beta adrenergic receptors. Thorax. 1987;42:100-4.
30. Ray MS, Singh V. Comparison of nebulized adrenaline versus salbutamol in wheeze associated respiratory tract infection in infants. Indian Pediatr. 2002;39:12-22.
31. Delgado A, Chou KJ, Silver EJ, Crain EF. Nebulizers vs metered-dose inhalers with spacers for bronchodilator therapy to treat wheezing in children aged 2 to 24 months in a pediatric emergency department. Arch Pediatr Adolesc Med. 2003; 157:76-80.
32. Hofhuis W, Van der Wiel EC, Tiddens HA, Brinkhorst G, Holland WP, De Jongste JC, et al. Bronchodilation in infants with malacia or recurrent wheeze. Arch Dis Child. 2003;88:246-9.
33. Chavasse R, Seddon P, Bara A, McKean M. Short acting beta agonists for recurrent wheeze in children under 2 years of age. Cochrane Database Syst Rev. 2002;CD002873.
34. Rubilar L, Castro-Rodríguez JA, Girardi G. Randomized trial of salbutamol via metered-dose inhaler with spacer versus nebulizer for acute wheezing in children less than 2 years of age. Pediatr Pulmonol. 2000;29:264-9.
35. Wildhaber JH, Devadason SG, Hayden MJ, Eber E, Summers QA, LeSouef PN. Aerosol delivery to wheezy infants: A comparison between a nebulizer and two small volume spacers. Pediatr Pulmonol. 1997;23:212-6.
36. Benito Fernández J, Mintegui Raso S, Sánchez Echaniz J, Vázquez Ronco MA, Pijoán Zubizarreta JI. Eficacia de la administración precoz de bromuro de ipratropio nebulizado en niños con crisis de asma. An Esp Pediatr. 2000;53:217-22.
37. Zorc JJ, Pusic MV, Ogborn CJ, Lebet R, Duggan AK. Ipratropium bromide added to asthma treatment in the pediatric emergency department. Pediatrics. 1999;103:748-52.
38. Qureshi F, Pestian J, Davis P, Zaritsky A. Effect of nebulized ipratropium on the hospitalization rates of children with asthma. N Engl J Med. 1998;339:1030-5.
39. Everard ML, Bara A, Kurian M, Elliott TM, Ducharme F. Anticholinergic drugs for wheeze in children under the age of two years. Cochrane Database Syst Rev. 2002;CD001279.
40. Goggin N, Macarthur C, Parkin PC. Randomized trial of the addition of ipratropium bromide to albuterol and corticosteroid therapy in children hospitalized because of an acute asthma exacerbation. Arch Pediatr Adolesc Med. 2001;155:1329-34.
41. Craven D, Kercsmar CM, Myers TR, O'riordan MA, Golonka G, Moore S. Ipratropium bromide plus nebulized albuterol for the treatment of hospitalized children with acute asthma. J Pediatr. 2001;138:51-8.
42. Tal A, Levy N, Bearman JE. Methylprednisolone therapy for acute asthma in infants and toddlers: A controlled clinical trial. Pediatrics. 1990;86:350-6.
43. Daugbjerg P, Brenoe E, Forchhammer H, Frederiksen B, Glazowski MJ, Ibsen KK, et al. A comparison between nebulized terbutaline, nebulized corticosteroid and systemic corticosteroid for acute wheezing in children up to 18 months of age. Acta Paediatr. 1993;82:547-51.
44. Becker JM, Arora A, Scarfone RJ, Spector ND, Fontana-Penn ME, Gracely E, et al. Oral versus intravenous corticosteroids in children hospitalized with asthma. J Allergy Clin Immunol. 1999;103:586-90.
45. Barnett PL, Caputo GL, Baskin M, Kuppermann N. Intravenous versus oral corticosteroids in the management of acute asthma in children. Ann Emerg Med. 1997;29:212-7.
46. Scarfone RJ, Fuchs SM, Nager AL, Shane SA. Controlled trial of oral prednisone in the emergency department treatment of children with acute asthma. Pediatrics. 1993;92:513-8.
47. Schuh S, Reisman J, Alshehri M, Dupuis A, Corey M, Arseneault R, et al. A comparison of inhaled fluticasone and oral prednisone for children with severe acute asthma. N Engl J Med. 2000;343:689-94.
48. Nakanishi AK, Klasner AK, Rubin BK. A randomized controlled trial of inhaled flunisolide in the management of acute asthma in children. Chest. 2003;124:790-4.
49. Escribano Montaner A, Ibero Iborra M, Garde Garde J, Gartner S, Villa Asensi J, Pérez Frías J. Protocolos terapéuticos en asma infantil. En: Protocolos Diagnóstico-terapéuticos AEP. Neumología y Alergia. Madrid: Asociación Española de Pediatría; 2003. p. 187-210.
50. Ibero Iborra M, Escribano Montaner A, Sirvent Gómez J, García Hernández G, Martínez Gimeno A. Fernández Benítez M. Protocolos diagnósticos en asma bronquial. En: Protocolos Diagnóstico-terapéuticos AEP. Neumología y Alergia. Madrid: Asociación Española de Pediatría; 2003. p. 171-86.
51. Comité de asma de la SEICAP. Guía para la atención del niño asmático. Protocolo diagnóstico y terapéutico del asma infantil. Allergol Immunopathol (Madr). 2000;28:1-63.
52. García-Marcos L, Garde Garde J, Escribano Montaner A, Malmierca Sánchez F. Asma en Pediatría. Barcelona: Edipharma; 2002.
53. Tal A, Simon G, Vermeulen JH, Petru V, Cobos N, Everard ML, et al. Budesonide/formoterol in a single inhaler versus inhaled corticosteroids alone in the treatment of asthma. Pediatr Pulmonol. 2002;34:342-50.
54. Van den Berg NJ, Ossip MS, Hederos CA, Anttila H, Ribeiro BL, Davies PI. Salmeterol/fluticasone propionate (50/100 microg) in combination in a Diskus inhaler (Seretide) is effective and safe in children with asthma. Pediatr Pulmonol. 2000; 30:97-105.
55. Martínez FD. Development of wheezing disorders and asthma in preschool children. Pediatrics. 2002;109:362-7.
56. Bisgaard H. Persistent wheezing in very young preschool children reflects lower respiratory inflammation. Am J Respir Crit Care Med. 2001;163:1290-1.
57. McKean M, Ducharme F. Inhaled steroids for episodic viral wheeze of childhood. Cochrane Database Syst Rev. 2000; CD001107.
58. Reinhardt D, Zehmisch T, Becker B, Nagel-Hiemke M. Age-dependency of alpha- and heta-adrenoceptors on thrombocytes and lymphocytes of asthmatic and nonasthmatic children. Eur J Pediatr. 1984;142:111-6.
59. Bisgaard H, Munck SL, Nielsen JP, Petersen W, Ohlsson SV. Inhaled budesonide for treatment of recurrent wheezing in early childhood. Lancet. 1990;336:649-51.
60. Bisgaard H, Gillies J, Groenewald M, Maden C. The effect of inhaled fluticasone propionate in the treatment of young asthmatic children: A dose comparison study. Am J Respir Crit Care Med. 1999;160:126-31.
61. Connett GJ, Warde C, Wooler E, Lenney W. Use of budesonicle in severe asthmatics aged 1-3 years. Arch Dis Child. 1993; 69:351-5.
62. De Blic J, Delacourt C. Le Bourgeois M, Mahut B, Ostinelli J, Caswell C, et al. Efficacy of nebulized budesonide in treatment of severe infantile asthma: A double-blind study. J Allergy Clin Immunol. 1996;98:14-20.
63. Gleeson JG, Price JK Controlled trial of budesonide given by the nebuhaler in preschool children with asthma. BMJ. 1988; 297:163-6.
64. Teper AM, Colom AJ. Kofman CD, Maffey AF, Vidaurreta SM, Bergada I. Effects of inhaled fluticasone propionate in children less than 2 years old with recurrent wheezing. Pediatr Pulmonol. 2004;37:111-5.
65. Noble V, Ruggins NR, Everard ML, Milner AD. Inhaled budesonide for chronic wheezing under 18 months of age. Arch Dis Child. 1992;67:285-8.
66. Fox GF, Everard ML, Marsh MJ, Milner AD. Randomized controlled trial of budesonide for the prevention of post-bronchiolitis wheezing. Arch Dis Child. 1999;80:343-7.
67. Kajosaari M, Syvanen P. Forars M, Juntunen-Backman K. Inhaled corticosteroids during and after respiratory syncytial virus-bronchiolitis may decrease subsequent asthma. Pediatr Allergy Immunol. 2000;11:198-202.
68. Reijonen T, Korppi M, Kuikka L. Renies K. Anti-inflammatory therapy reduces wheezing after bronchiolitis. Arch Pediatr Adolesc Med. 1996;150:512-7.
69. Bisgaard H. A randomized trial of montelukast in respiratory syncytial virus postbronchiolitis. Am J Respir Crit Care Med. 2003;167:379-83.
70. Straub DA, Moeller A, Minocchieri S, Hamacher J, Sennhauser FH, Hall GL, et al. The effect of montelukast on lung function and exhaled nitric oxide in infants with early childhood asthma. Eur Respir J. 2005;25:289-94.
71. Sekhsaria S, Alam M, Sait T, Starr B, Parekh M. Efficacy and safety of inhaled corticosteroids in combination with a long-acting beta2-agonist in asthmatic children under age 5. J Asthma. 2004;41:575-82.
72. Glass J, Archer LN, Adams W, Simpson H. Nebulised cromoglycate, theophylline, and placebo in preschool asthmatic children. Arch Dis Child. 1981;56:648-51.
73. Bertelsen A, Andersen JB, Busch P, Daugbjerg P, Friis B, Hansen L, et al. Nebulised sodium cromoglycate in the treatment of wheezy bronchitis. A multicentre double-blind placebo controlled study. Allergy. 1986;41:266-70.
74. Conway SP, Houlsby WT. Slow release theophylline in preschool asthmatics. Arch Dis Child. 1986;61:1024-6.
75. Furfaro S, Spier S, Drblik SP, Turgeon JP, Robert M. Efficacy of cromoglycate in persistently wheezing infants. Arch Dis Child. 1994;71:331-4.
76. Tasche MJ, Van der Wouden JC, Uijen JH, Ponsioen BP, Bernsen RM, Suijlekom-Smit LW, et al. Randomized placebo-controlled trial of inhaled sodium cromoglycate in 1-4-year-old children with moderate asthma. Lancet. 1997;350:1060-4.
77. Geller-Bernstein C, Levin S. Nebulised sodium cromoglycate in the treatment of wheezy bronchitis in infants and young children. Respiration. 1982;43:294-8.
78. Cogswell JJ, Simpkiss MJ. Nebulised sodium cromoglycate in recurrently wheezy preschool children. Arch Dis Child. 1985; 60:736-8.
79. Baran D. A comparison of inhaled budesonide and beclomethasone dipropionate in childhood asthma. Br J Dis Chest. 1987;81:170-5.
80. Price JF, Weller PH. Comparison of fluticasone propionate and sodium cromoglycate for the treatment of childhood asthma (an open parallel group study). Respir Med. 1995;89:363-8.
81. Petersen W, Karup-Pedersen F, Friis B, Howitz P, Nielsen F, Stromquist LH. Sodium cromoglycate as a replacement for inhaled corticosteroids in mild-to-moderate childhood asthma. Allergy. 1996;51:870-5.
82. Peden DB, Berger WE, Noonan MJ, Thomas MR, Hendricks VL, Hamedani AG, et al. Inhaled fluticasone propionate delivered by means of two different multidose powder inhalers is effective and safe in a large pediatric population with persistent asthma. J Allergy Clin Immunol. 1998;102:32-8.
83. Baker JW, Mellon M, Wald J, Welch M, Cruz-Rivera M, Walton-Bowen K. A multiple-dosing, placebo-controlled study of budesonide inhalation suspension given once or twice daily for treatment of persistent asthma in young children and infants. Pediatrics. 1999;103:414-21.
84. Ferguson AC, Spier S, Manjra A, Versteegh FG, Mark S, Zhang P. Efficacy and safety of high-dose inhaled steroids in children with asthma: A comparison of fluticasone propionate with budesonide. J Pediatr. 1999;134:422-7.
85. Mellon M. Efficacy of budesonide inhalation suspension in infants and young children with persistent asthma. Budesonide Inhalation Suspension Study Group. J Allergy Clin Immunol. 1999;104:191-9.
86. Long-term effects of budesonide or nedocromil in children with asthma. The Childhood Asthma Management Program Research Group. N Engl J Med. 2000;343:1054-63.
87. Nielsen KG, Bisgaard H. The effect of inhaled budesonide on symptoms, lung function, and cold air and methacholine responsiveness in 2- to 5-year-old asthmatic children. Am J Respir Crit Care Med. 2000;162:1500-6.
88. Arets HG, Kamps AW, Brackel HJ, Mulder PG, Vermue NA, Van der Ent CK. Children with mild asthma: Do they benefit from inhaled corticosteroids? Eur Respir J. 2002;20:1470-5.
89. Verona E, Petrov D, Cserhati E, Hofman J, Geppe N, Medley H, et al. Fluticasone propionate in asthma: A long term dose comparison study. Arch Dis Child. 2003;88:503-9.
90. Lenney W, Pedersen S, Boner AL, Ebbutt A, Jenkins MM. Efficacy and safety of salmeterol in childhood asthma. Eur J Pediatr. 1995;154:983-90.
91. Bensch G, Berger WE, Blokhin BM, Socolovsky AL, Thomson MH, Till MD, et al. One-year efficacy and safety of inhaled formoterol dry powder in children with persistent asthma. Ann Allergy Asthma Immunol. 2002;89:180-90.
92. Pearlman DS, Lampl KL, Dowling PJ Jr, Miller CJ, Bonuccelli CM. Effectiveness and tolerability of zafirlukast for the treatment of asthma in children. Clin Ther. 2000;22:732-47.
93. Knorr B, Matz J, Bernstein JA, Nguyen H, Seidenberg BC, Reiss TF, et al. Montelukast for chronic asthma in 6- to 14-year-old children: A randomized, double-blind trial. Pediatric Montelukast Study Group. JAMA. 1998;279:1181-6.
94. Meyer KA, Arduino JM, Santanello NC, Knorr BA, Bisgaard H. Response to montelukast among subgroups of children aged 2 to 14 years with asthma. J Allergy Clin Immunol. 2003;111:757-62.
95. Simons FE, Villa JR, Lee BW, Teper AM, Lyttle B, Aristizábal G, et al. Montelukast added to budesonide in children with persistent asthma: A randomized, double-blind, crossover study. J Pediatr. 2001;138:694-8.
96. Bisgaard H, Zielen S, García-García ML, Johnston SL, Gilles L, Menten J, et al. Montelukast reduces asthma exacerbations in 2- to 5-year-old children with intermittent asthma. Am J Respir Crit Care Med. 2005;171:315-22.
97. Van der Wouden JC, Tasche MJ, Bernsen RM, Uijen JH, De Jongste JC, Ducharme FM. Inhaled sodium cromoglycate for asthma in children. Cochrane Database Syst Rev. 2003; CD002173.
98. Russell G, Williams DA, Weller P, Price JF. Salmeterol xinafoate in children on high dose inhaled steroids. Ann Allergy Asthma Immunol. 1995;75:423-8.
99. Nelson HS, Chapman KR, Pyke SD, Johnson M, Pritchard JN. Enhanced synergy between fluticasone propionate and salmeterol inhaled from a single inhaler versus separate inhalers. J Allergy Clin Immunol. 2003;112:29-36.
100. Abramson M, Puy R, Weiner J. Allergen immunotherapy for asthma. Cochrane Database Syst Rev. 2003;4:CD001186.
101. Abramson M, Puy R, Weiner J. Immunotherapy in asthma: An updated systematic review. Allergy. 1999;54:1022-41.
102. Abramson MJ, Puy RM, Weiner JM. Allergen immunotherapy for asthma. Cochrane Database Syst Rev. 2000;CD001186.
103. Abramson MJ, Puy RM, Weiner JM. Is allergen immunotherapy effective in asthma? A meta-analysis of randomized controlled trials. Am J Respir Crit Care Med. 1995;151:969-74.
104. Bousquet J, Lockey R, Mailing HJ. WHO position paper. Allergen immunotherapy: Therapeutic vaccines for allergic diseases. Allergy. 1998;53 Suppl:1-42.
105. Canonica GW, Passalacqua G. Noninjection routes for immunotherapy. J Allergy Clin Immunol. 2003;111:437-48.
106. Wilson DR, Torres LI, Durham SR. Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst Rev. 2003; CD002893.
107. Lockey RF, Benedict LM, Turkeltaub PC, Bukantz SC. Fatalities from immunotherapy (IT) and skin testing (ST). J Allergy Clin Immunol. 1987;79:660-77.
108. Newman SP, Clarke SW. Therapeutic aerosols 1-physical and practical considerations. Thorax. 1983;38:881-6.
109. Clarke SW, Newman SP. Therapeutic aerosols 2-Drugs available by the inhaled route. Thorax. 1984;39:1-7.
110. O'Callaghan C, Barry PW. How to choose delivery devices for asthma. Arch Dis Child. 2000;82:185-7.
111. Pedersen S, Frost L, Arnfred T. Errors in inhalation technique and efficiency in inhaler use in asthmatic children. Allergy. 1986;41:118-24.
112. Pauwels R, Newman S, Borgstrom L. Airway deposition and airway effects of antiasthma drugs delivered from metered-dose inhalers. Eur Respir J. 1997;10:2127-38.
113. Brown PH, Greening AP, Crompton GK. Large volume spacer devices and the influence of high dose beclomethasone dipropionate on hypothalamo-pituitary- adrenal axis function. Thorax. 1993;48:233-8.
114. Lowenthal D, Kattan M. Facemasks versus mouthpieces for aerosol treatment of asthmatic children. Pediatr Pulmonol. 1992;14:192-6.
115. Sánchez Jiménez J, Gairi J, Miró X, Cobos N. Tractament inhalatori en el nen. Dispositius i tècniques d'administració en nens menors de 5 anys (I). Pediatr Catalana. 1998;58:89-97.
116. Sánchez Jiménez J, Gairi J, Miró X, Cobos N. Tractament inhalatori en el nen. Dispositius i tècniques d'administració en nens de mes de 5 anys (II). Pediatr Catalana. 1998;58:231-51.
117. Taburet AM, Schmit B. Pharmacokinetic optimisation of asthma treatment. Clin Pharmacokinet. 1994;26:396-418.
118. Bisgaard H, Klug B, Sumby BS, Burnell PK. Fine particle mass from the Diskus inhaler and Turbuhaler inhaler in children with asthma. Eur Respir J. 1998;11:1111-5.
119. Newhouse MT. Asthma therapy with aerosols: Are nebulizers obsolete? A continuing controversy. J Pediatr. 1999;135:5-8.
120. Ram FS, Wright J, Brocklebank D, White JE. Systematic review of clinical effectiveness of pressurised metered dose inhalers versus other hand held inhaler devices for delivering beta (2) agonists bronchodilators in asthma. BMJ. 2001;323:901-5.